Therapeutic Challenges to Retinitis Pigmentosa: From Neuroprotection to Gene Therapy
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Syndromic retinitis pigmentosa (RP) is the result of several mutations expressed in rod photoreceptors, over 40 of which have so far been identified. Enormous efforts are being made to relate the advances in unraveling the patho-physiological mechanisms to therapeutic approaches in animal models, and eventually in clinical trials on humans. This review summarizes briefly the current clinical management of RP and focuses on the new exciting treatment possibilities. To date, there is no approved therapy able to stop the evolution of RP or restore vision. The current management includes an attempt at slowing down the degenerative process by vitamin supplementation, trying to treat ocular complications and to provide psychological support to blind patients. Novel therapeutic may be tailored dependant on the stage of the disease and can be divided in three groups. In the early stages, when there are surviving photoreceptors, the first approach would be to try to halt the degeneration by correction of the underlying biochemical abnormality in the visual cycle using gene therapy or pharmacological treatment. A second approach aims to cope with photoreceptor cell death using neurotrophic growth factors or anti-apoptotic factors, reducing the production of retino-toxic molecules, and limiting oxidative damage. In advanced stages, when there are few or no functional photoreceptors, strategies that may benefit include retinal transplantation, electronic retinal implants or a newly described optogenetic technique using a light-activated channel to genetically resensitize remnant cone-photoreceptor cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human photoreceptor topography
Curcio, C. A., Sloan, K. R., Kalina, R. E., & Hendrickson, A. E. (1990) · Journal of Comparative Neurology · doi:10.1002/cne.902920402 · Cited by 3,167
Hartong, D. T., Berson, E. L., & Dryja, T. P. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69740-7 · Cited by 2,924
The Retinal Pigment Epithelium in Visual Function
Strauss, O. (2005) · Physiological Reviews · doi:10.1152/physrev.00021.2004 · Cited by 2,828
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 1×
“Three human clinical trials using AAV serotype 2 reported their findings separately in 9 patients in 2008 [39-41].”
BackgroundEffect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 2×
“Future treatment for retinal degeneration due to photoreceptor cell loss may require a combination of gene and cell therapeutic strategies [39, 95].”
BackgroundGene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202 · cited 1×
“Preliminary trials involving surgical delivery of recombinant AAV carrying wild type rpe65 into the subretinal space of the Briard dog, a natural occurring model with mutation in the RPE65 gene, demonstrated dramatic improvements in the light sensitivity of rods and cones [31-35].”
BackgroundHamel, C. (2006) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-1-40 · Cited by 962
Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954 · cited 1×
“Three human clinical trials using AAV serotype 2 reported their findings separately in 9 patients in 2008 [39-41].”
BackgroundMaguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865 · cited 1×
“The greatest improvement was noted in children, all of who gained ambulatory vision, suggesting that early intervention would result in the best potential gain [44].”
BackgroundSubretinal electronic chips allow blind patients to read letters and combine them to words
Zrenner, E., Bartz-Schmidt, K. U., Benav, H., Besch, D., Bruckmann, A., Gabel, V.-P., Gekeler, F., Greppmaier, U., Harscher, A., Kibbel, S., et al. (2011) · Proceedings of the Royal Society B: Biological Sciences · doi:10.1098/rspb.2010.1747 · Cited by 819 · cited 1×
“For example, if viruses are used to genomically alter the cells, the expression of oncogenes may potentially be triggered [90].”
BackgroundG Protein–Coupled Receptor Rhodopsin
Palczewski, K. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142743 · Cited by 764
Rizzo, J. F., Wyatt, J., Loewenstein, J., Kelly, S., & Shire, D. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.02-0817 · Cited by 478 · cited 1×
“Recent development of human iPSC and the ability to specifically induce differentiation into cells with human photoreceptor phenotype has now provided us with the opportunity for embryo-free autologous transplantation and opens a new path in retinal transplant [91].”
BackgroundA Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa
Berson, E. L. (1993) · Archives of Ophthalmology · doi:10.1001/archopht.1993.01090060049022 · Cited by 465
Diseases Caused by Defects in the Visual Cycle: Retinoids as Potential Therapeutic Agents
Travis, G. H., Golczak, M., Moise, A. R., & Palczewski, K. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105225 · Cited by 419
Cell survival matters: docosahexaenoic acid signaling, neuroprotection and photoreceptors
Bazan, N. G. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2006.03.005 · Cited by 353
Ahuja, A. K., Dorn, J. D., Caspi, A., McMahon, M. J., Dagnelie, G., daCruz, L., Stanga, P., Humayun, M. S., Greenberg, R. J., & Argus II Study Group (2011) · British Journal of Ophthalmology · doi:10.1136/bjo.2010.179622 · Cited by 289 · cited 1×
“Recently, in a study on the largest cohort of visual prosthesis recipients to date (27 patients), they found that artificial vision augments information from existing vision in a spatial-motor task [75].”
BackgroundGene Therapy with Viral Vectors
Kootstra, N. A., & Verma, I. M. (2003) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.140257 · Cited by 267 · cited 1×
“Adeno-associated virus (AAV), a nonpathogenic parvovirus, has been the most successful vector owing to its ability to transduce a variety of non-dividing cell types [28, 29].”
BackgroundLeber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy
Cideciyan, A. V. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.04.002 · Cited by 256 · cited 1×
“Human results suggest that there may even be differences between foveal and extra-foveal cones and this may explain the lack of foveal functional improvement demonstrable with gene therapy to date [97].”
BackgroundVan Hooser, J. P., Aleman, T. S., He, Y.-G., Cideciyan, A. V., Kuksa, V., Pittler, S. J., Stone, E. M., Jacobson, S. G., & Palczewski, K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.150236297 · Cited by 252 · cited 1×
“The first experiments aimed at bypassing the biochemical defect caused by the absence of RPE65 were performed by oral administration of 9-cis-retinyl acetate in RPE65deficient mice [49, 50].”
BackgroundWeber, M., Rabinowitz, J., Provost, N., Conrath, H., Folliot, S., Briot, D., Chérel, Y., Chenuaud, P., Samulski, J., Moullier, P., et al. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00098-4 · Cited by 203
Tsybovsky, Y., Molday, R. S., & Palczewski, K. (2010) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4419-5635-4_8 · Cited by 200 · cited 1×
“During the process of disk shedding, these compounds, of which the best studied is A2E, accumulate in the cells of RPE, which ultimately leads to RPE cell death and concomitant degeneration of photoreceptors [12].”
BackgroundClinical Trial of Lutein in Patients With Retinitis Pigmentosa Receiving Vitamin A
(2010) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2010.32 · Cited by 179
Recovery of Visual Functions in a Mouse Model of Leber Congenital Amaurosis
Van Hooser, J. P., Liang, Y., Maeda, T., Kuksa, V., Jang, G.-F., He, Y.-G., Rieke, F., Fong, H. K. W., Detwiler, P. B., & Palczewski, K. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m112384200 · Cited by 154 · cited 1×
“The first experiments aimed at bypassing the biochemical defect caused by the absence of RPE65 were performed by oral administration of 9-cis-retinyl acetate in RPE65deficient mice [49, 50].”
Background
Cited by
Dias, M. F., Joo, K., Kemp, J. A., Fialho, S. L., da Silva Cunha, A., Woo, S. J., & Kwon, Y. J. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.10.004 · Cited by 413
Chemistry of the Retinoid (Visual) Cycle
Kiser, P. D., Golczak, M., & Palczewski, K. (2014) · Chemical Reviews · doi:10.1021/cr400107q · Cited by 353
Long-Term Results from an Epiretinal Prosthesis to Restore Sight to the Blind
Ho, A. C., Humayun, M. S., Dorn, J. D., da Cruz, L., Dagnelie, G., Handa, J., Barale, P.-O., Sahel, J.-A., Stanga, P. E., Hafezi, F., et al. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.04.032 · Cited by 260
Alambiaga-Caravaca, A. M., Calatayud-Pascual, M. A., Rodilla, V., Concheiro, A., López-Castellano, A., & Alvarez-Lorenzo, C. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12080702 · Cited by 38
“In advanced stages, when there are barely any functional photoreceptors left, retinal transplantation or electronic retinal implants may be needed [4].”
BackgroundGene Therapy for Inherited Retinal Degeneration
Arbabi, A., Liu, A., & Ameri, H. (2019) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2018.0087 · Cited by 30
“Gene therapy methods, which are used to replace or correct abnormal genes, can be classified into 2 main categories 7,8 : (1) gene augmentation or replacement, in which a functional copy of the mutant gene is inserted into the host cells using viral or nonviral vectors and (2) gene disruption or…”
Metadata
- Authors
- N. Sahni, J., Angi, M., Irigoyen, C., Angi, M., Semeraro, F., R. Romano, M., Parmeggiani, F., & Parmeggiani, F.
- Venue
- Current Genomics
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2011-06-01
- Volume
- 12
- Issue
- 4
- Pages
- 276-284
- ISSN
- 1389-2029 (ISSN-L)
- OpenAlex
- W1999874860
- Cited by
- 69
- References
- 23
- FWCI
- 2.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.